Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Feasibility and safety of SGLT2 inhibition by empagliflozin for the preservation of pancreas function in recent-onset type 1 diabetes

Next Previous
X
Search
Trial Profile

Feasibility and safety of SGLT2 inhibition by empagliflozin for the preservation of pancreas function in recent-onset type 1 diabetes

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 25 Feb 2020

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Empagliflozin (Primary)
  • Indications Type 1 diabetes mellitus
  • Focus Adverse reactions

    • Most Recent Events

    • 24 Feb 2020 Status changed from active, no longer recruiting to completed.
    • 15 Jan 2019 Planned End Date changed from 31 Mar 2019 to 30 Jun 2019.
    • 15 Jan 2019 Status changed from recruiting to active, no longer recruiting.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top